Hiromitsu Kumada
Overview
Explore the profile of Hiromitsu Kumada including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
518
Citations
10519
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kudo M, Ren Z, Guo Y, Han G, Lin H, Zheng J, et al.
Lancet
. 2025 Jan;
405(10474):203-215.
PMID: 39798578
Background: Transarterial chemoembolisation (TACE) is standard care for unresectable, non-metastatic hepatocellular carcinoma. We aimed to evaluate the addition of lenvatinib and pembrolizumab to TACE versus dual placebo plus TACE in...
2.
Kawamura Y, Akuta N, Yamamoto S, Eriksson Y, Hosaka T, Saitoh S, et al.
Cureus
. 2024 Dec;
16(11):e74415.
PMID: 39723267
Background: This case series evaluated the clinical impact and significant technical points of transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) using the smaller drug-eluting bead (DEB) M1 (DC Bead M1;...
3.
Kawamura Y, Akuta N, Yamamoto S, Eriksson Y, Hosaka T, Saitoh S, et al.
Cureus
. 2024 Nov;
16(10):e72352.
PMID: 39588457
Background and objective Drug-eluting beads (DEB) have been highly useful in the current treatment strategies for multiple and large hepatocellular carcinomas (HCC) with or without systemic therapy. Recently, smaller beads...
4.
Kawamura Y, Akuta N, Shindoh J, Matsumura M, Okubo S, Tominaga L, et al.
Hepatol Res
. 2024 Sep;
PMID: 39324582
Background: The aim of this study was to evaluate the newly established oncological criteria of resectability of hepatocellular carcinoma (HCC) for selecting suitable candidates for systemic and combination therapy. Methods:...
5.
Kudo M, Finn R, Ikeda M, Sung M, Baron A, Okusaka T, et al.
Liver Cancer
. 2024 Aug;
13(4):451-458.
PMID: 39114764
Introduction: Lenvatinib (dosing for patients who weigh ≥60 kg was 12 mg/day; for patients who weigh <60 kg, the dose was 8 mg/day) plus pembrolizumab 200 mg once every 3...
6.
Akuta N, Kawamura Y, Sezaki H, Nakamichi K, Saegusa E, Ogura H, et al.
Intern Med
. 2024 May;
64(1):47-54.
PMID: 38719593
Objective The long-term impact of personalized diet and exercise programs for steatotic liver disease (SLD) remains unclear. Materials The subjects of this retrospective cohort study included 104 consecutive Japanese patients...
7.
Kawamura Y, Akuta N, Fujiyama S, Hosaka T, Saitoh S, Sezaki H, et al.
Hepatol Res
. 2023 Dec;
54(5):479-486.
PMID: 38112258
Aim: The aim of this study was to evaluate the use of a new classification for safer transradial access hepatic interventional radiology, based on preoperative evaluation of the location of...
8.
Tseng T, Hosaka T, Liu C, Suzuki F, Chiang C, Hong C, et al.
JHEP Rep
. 2023 Dec;
6(1):100956.
PMID: 38089551
Background & Aims: Risk scores have been designed to predict the development of hepatocellular carcinoma (HCC) in treatment-naive patients with chronic hepatitis B (CHB). However, little is known about their...
9.
Llovet J, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, et al.
Lancet Oncol
. 2023 Dec;
24(12):1399-1410.
PMID: 38039993
Background: Systemic therapies have improved the management of hepatocellular carcinoma, but there is still a need to further enhance overall survival in first-line advanced stages. This study aimed to evaluate...
10.
Kawamura Y, Akuta N, Fujiyama S, Suzuki F, Kumada H
Cureus
. 2023 Oct;
15(9):e45385.
PMID: 37854758
Many systemic chemotherapies, including immune checkpoint inhibitors (ICI), are now available for the treatment of advanced hepatocellular carcinoma. On the other hand, it is often difficult to continue administration of...